Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07164469
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Fludarabine — DRUG
    Given by IV
  • Cyclophosphamide — DRUG
    Given by IV
  • CD70.CAR NK Cells — DRUG
    Given by IV Infusion
  • Rimiducid (AP1903) — DRUG
    Given by IV Infusion

Study Details

This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.

Key Dates

Start date
Jun 28, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2031
Completion
Sep 30, 2033

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1st Dose: Treatment with Rimiducid + CD70.CAR NK Cells for Patients with DLBCL and HL
    Patients will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide from days -5 to -3, prior to infusion of CD70.CAR NK cells on day 0, on an outpatient or inpatient as clinically indicated.
  • Experimental: 2nd Dose: Treatment with Rimiducid + CD70.CAR NK Cells for Patients with DLBCL and HL
    Patients will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide from days -5 to -3, prior to infusion of CD70.CAR NK cells on day 0, on an outpatient or inpatient as clinically indicated.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Yago Nieto, MD,PHD
[email protected]
713-794-1752
Yago Nieto, MD,PHD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies